Detail page

Knowledge Web

Person

Bipin N. Savani

Arzt

Name	Bipin N. Savani
Place	USA
Profession	Arzt (characteristic profession)
Variant	Bipin Savani
Record type	Person
GND-Identifier	1066325146
Record ID	1066325146
Involved in show all Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT Efficacy and safety of outpatient fludarabine, cyclophosphamide, and rituximab based allogeneic hematopoietic cell transplantation in adults with severe aplastic anemia Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients GVHD like skin eruption post-autologous stem cell transplantation Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation Correction: Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT Correction: Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients Leukemia Reduced relapse incidence with FLAMSA-RIC compared with Busulfan/Fludarabine for acute myelogenous leukemia patients in first or second complete remission: a study from the acute leukemia working party of the european society for blood and marrow transplantation Clinical Guide to Transplantation in Lymphoma Clinical Guide to Transplantation in Lymphoma Blood and Marrow Transplantation Long Term Management : Prevention and Complications Blood and Marrow Transplantation Long Term Management : Prevention and Complications

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Bipin N. Savani

Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide

Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission

Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT

Efficacy and safety of outpatient fludarabine, cyclophosphamide, and rituximab based allogeneic hematopoietic cell transplantation in adults with severe aplastic anemia

Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis

Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients

GVHD like skin eruption post-autologous stem cell transplantation

Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT

Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients

Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation

Correction: Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party

Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia

Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT

Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT

Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia

Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT

Correction: Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis

Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis

Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

Leukemia

Reduced relapse incidence with FLAMSA-RIC compared with Busulfan/Fludarabine for acute myelogenous leukemia patients in first or second complete remission: a study from the acute leukemia working party of the european society for blood and marrow transplantation

Clinical Guide to Transplantation in Lymphoma

Clinical Guide to Transplantation in Lymphoma

Blood and Marrow Transplantation Long Term Management : Prevention and Complications

Blood and Marrow Transplantation Long Term Management : Prevention and Complications